the acute myeloid leukemia includes an heterogeneous spectrum of diseases of malignant and clonal origin representing a challenge of the current medicine. with the exception of the pro-myelocytic, the achieved therapeutical results continue being discouraging. recently are available data demonstrating better results with the use of high doses of anthracycline in the induction. this is the first case in cuba where in induction it was used the 100 mg/m2 rubidomicin plus 100 mg/m2 for three days plus 100 mg/m2 arabinoside for seven days, both in continuous intravenous infusion. the clinical course is satisfactory until now. authors made a brief review of medical literature in this respect.